<- Go Home
Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. develops novel therapeutic products for the acute treatment of migraines. Its product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery devices. The company was incorporated in 2016 and is based in Durham, North Carolina. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.
Market Cap
$36.5M
Volume
282.9K
Cash and Equivalents
$19.5M
EBITDA
-$53.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$8.08
52 Week Low
$0.59
Dividend
N/A
Price / Book Value
0.97
Price / Earnings
-0.55
Price / Tangible Book Value
0.97
Enterprise Value
-$4.8M
Enterprise Value / EBITDA
0.09
Operating Income
-$54.4M
Return on Equity
104.04%
Return on Assets
-49.62
Cash and Short Term Investments
$41.4M
Debt
$116.0K
Equity
$37.6M
Revenue
N/A
Unlevered FCF
-$24.9M
Sector
Pharmaceuticals
Category
N/A